| Congresso Brasileiro de Microbiologia 2023 | Resumo: 1057-1 | ||||
Resumo:Cancer is considered one of the main causes of death worldwide and can be associated with several factors, such as genetic mutations, exposure to chemical products and radiation, alcoholism, and diet, among others. Among the various types of cancer, cervical cancer is among the most recurrent, with melanoma being one of the most metastatic and hepatocarcinoma being the most common neoplasm of the liver, with a high lethality rate. For the treatment of these diseases, some drugs are administered, which cause strong side effects in patients, which can affect normal cells in the body and induce resistance in tumor cells. For this reason, new antitumor compounds are being sought, and microorganisms from limiting environments, such as cave bacteria, may be potential producers of such substances. In the present study, the cave bacteria Bacillus sp. CMA 12 and Lysinibacillus sp. CMA 21 were tested against the proliferation of cervical adenocarcinoma (HeLa), human hepatocarcinoma (HUH), murine (B16F10) and human (Sy-mel) melanoma tumor cell lines. HeLa and B16F10 cells were incubated between 18 and 48 hours at 37°C and 5% CO2. Cytotoxic activity was tested using [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] (MTT). The viability and proliferation of HUH and Sy-mel cells were quantified by the indirect crystal violet method, and absorbances were read between 545 nm and 570 nm (Fig. 1).
The culture supernatant showed statistically significant results in the control of HeLa and B16F10 cell strains; however, only the supernatant of Lysinibacillus sp. CMA 21 controlled the HUH and Sy-mel strains. The results indicate that bacterial strains produce substances, possibly secondary metabolites and peptides, capable of reducing the viability of tumor cells, regulating gene expression and leading to apoptosis. To confirm these hypotheses, new tests will be performed next. It is concluded that cave bacteria can have antitumor potential and be explored as biotechnological products for the pharmaceutical industry.
Palavras-chave: cancer, cytotoxicity, secondary metabolites | |||||